Physician profile
Blake A Jacobs
NPI 1588191498
$336.10
in general payments reported to CMS, 2019-2025
11 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $25.58 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $59.99 | 2025 | Fasenra, Tezspire |
| Insmed, INC. | $57.70 | 2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.92 | 2024-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $31.43 | 2025 | Dupixent |
| Genzyme Corporation | $26.10 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.14 | 2025 | Glassia |
| Axsome Therapeutics, INC. | $20.34 | 2025 | Sunosi |
| Genentech USA, INC. | $18.88 | 2025 | Xolair |
| Viatris Specialty LLC | $18.71 | 2025 | Yupelri |
| Verona Pharma, INC. | $15.40 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $13.49 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.